Vaccine Therapy in Treating Patients With Breast Cancer

Clinical Trial ID NCT00524277

Rank	Title	Journal	Year	PubWeight™‹?›
1	Treatment of HER2-positive breast cancer: current status and future perspectives.	Nat Rev Clin Oncol	2011	4.12
2	Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.	Proc Natl Acad Sci U S A	2011	2.35
3	Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.	Cancer	2011	1.38
4	Anti-HER2 vaccines: new prospects for breast cancer therapy.	Cancer Immunol Immunother	2010	1.12
5	Predictions versus high-throughput experiments in T-cell epitope discovery: competition or synergy?	Expert Rev Vaccines	2012	0.88
6	Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials.	Expert Rev Vaccines	2011	0.84
7	Cancer immunoprevention--the next frontier.	Cancer Prev Res (Phila)	2014	0.82
8	Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.	Ann Oncol	2016	0.81
9	The Promise of Preventive Cancer Vaccines.	Vaccines (Basel)	2015	0.77
10	New clinical advances in immunotherapy for the treatment of solid tumours.	Immunology	2015	0.76
11	A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial.	J Immunother Cancer	2015	0.76